Transparency about risks and consistent messaging may reduce vaccine scepticism
Perceptions of government inaction or political interference with trials and regulatory approval may foster doubts about safety, write Barry Eichengreen, Cevat Giray Aksoy and Orkun Saka.
Monday, 9 November brought welcome news from Pfizer about the successful Phase 3 trial of what appears to be a 90 per cent effective COVID-19 vaccine. Stock markets reacted with elation, seeming to declare […]